SCHEMBL306653

SCHEMBL306653

CC(C(=O)O)C(=O)Nc1ccccc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.67
ALDH1A1 P00352 4/20 0.67
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
RXFP1 Q9HBX9 1/20 0.67
POLB P06746 2/20 0.57
GAA P10253 4/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
HPGD P15428 4/20 0.56
LMNA P02545 3/20 0.56
HTT P42858 2/20 0.56
ATM Q13315 2/20 0.56
NAPRT Q6XQN6 1/20 0.54
HSD17B10 Q99714 1/20 0.54
RAB9A P51151 2/20 0.53
HSP90AA1 P07900 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
TAAR1 Q96RJ0 1/20 0.53
GPR55 Q9Y2T6 1/20 0.53
MME P08473 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18852431 0.91 ALDH1A1 (0.66) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL224150 0.89 TAAR1 (0.70) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL4668132 0.86 ALDH1A1 (0.65) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL6834723 0.86 MAPT (0.55) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL14817491 0.86 ALDH1A1 (0.59) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL307289 0.84 MAPT (0.58) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL14580288 0.84 ALDH1A1 (0.62) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL27822637 0.84 GAA (0.72) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL11510700 0.83 ALDH1A1 (0.85) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL9886 0.83 ALDH1A1 (0.85) MAPTALDH1A1MEN1KMT2ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117264925-A Modified enzymes 牛津纳米孔科技公开有限公司 2023-12-22 CN disclosed
EP-1957498-B1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC (CA) 2017-02-15 EP disclosed
EP-1957498-B1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC (CA) 2017-02-15 EP disclosed
EP-2445886-B1 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS AMGEN INC (US) 2016-03-30 EP disclosed
EP-2445886-B1 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS AMGEN INC (US) 2016-03-30 EP disclosed
US-8940724-B2 Quinoline derivitives and their uses AMGEN INC. (US) 2015-01-27 US disclosed
US-8940724-B2 Quinoline derivitives and their uses AMGEN INC. (US) 2015-01-27 US disclosed
CN-103429576-A Novel processes for preparing triazolo[4,5-d]pyrimidine derivatives and intermediates thereof ACTAVIS GROUP PTC EHF 2013-12-04 CN disclosed
CN-103003231-A Novel method for preparing phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor ACTAVIS GROUP PTC EHF 2013-03-27 CN disclosed
US-8329726-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-12-11 US disclosed
US-20100331293-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-30 US disclosed
WO-2010151791-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed
WO-2010151791-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed
EP-1957498-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING MethylGene Inc. (CA) 2008-08-20 EP disclosed
WO-2008041053-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE, INC. (CA) 2008-04-10 WO disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed
CN-1207296-C Farnesyl transferase inhibiting 1, 2-annelated quinoline enantiomers JANSSEN PHARMACEUTICA NV (BE) 2005-06-22 CN disclosed
CN-1437601-A Farnesyl transferase inhibiting 1, 2-annelated quinoline enantiomers JANSSEN PHARMACEUTICA NV (BE) 2003-08-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 MAPT 2430/4885ALDH1A1 1649/4885MEN1 3655/4885
US-20100331293-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 MAPT 3291/4885ALDH1A1 4025/4885MEN1 1533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.